Melanocortin Receptor Expression on Skin Biopsies and Melanoma Risk
When a physician removes an unusual skin lesion, pathologists examine the tissue under a microscope to evaluate cellular architecture and assess malignancy. In recent years, researchers investigating the biology of pigment-producing skin cells have focused on cell surface proteins known as melanocortin receptors. In 2024, an observational investigation published in JCO Precision Oncology evaluated how the expression of the melanocortin-1 receptor (MC1R) correlates with distinct stages of tumor growth. Reviewing this paper provides useful context for how laboratory pathology investigates pigment cell biology and disease progression.
Why are researchers evaluating MC1R protein levels on melanoma tissue?
The melanocortin-1 receptor plays an essential role in human skin pigmentation and cellular DNA repair mechanisms. In healthy skin, MC1R signaling directs melanin production, a process detailed in our overview of MC1R and skin pigment. Because of its prominence on melanocytes, clinical trials have been actively investigating agents that specifically target MC1R in patients diagnosed with melanoma.
However, as noted in the study Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma, oncologists previously lacked large-scale human studies examining how frequently and intensely MC1R is expressed across primary and metastatic tissue samples. To determine whether the receptor could serve as a drug target or an indicator of disease severity, investigators needed to examine tissue cohorts spanning benign growths, localized skin tumors, and advanced disease.
How was the 2024 JCO Precision Oncology tissue study structured?
The investigative team conducted a laboratory analysis using tissue microarrays to evaluate MC1R protein expression across three distinct cohorts:
- 225 cases of benign nevi (non-cancerous moles)
- 189 cases of primary melanoma (tumors localized to the original skin site)
- 271 cases of metastatic melanoma (tumors that had spread to secondary sites)
To measure the quantity and pattern of receptor presence on these samples, the researchers applied quantitative immunofluorescence alongside standard immunohistochemistry staining. By using these quantitative laboratory techniques on tissue microarrays, the team could directly compare protein levels across early benign moles, localized primary lesions, and advanced metastatic tumors under identical laboratory conditions.
What did the study discover about receptor expression across disease stages?
The laboratory evaluation identified a clear, stepwise elevation in MC1R protein expression across the successive stages of melanoma progression. Benign nevi showed the lowest baseline expression, primary melanomas demonstrated intermediate levels, and metastatic samples exhibited the highest concentration of the receptor. This pattern demonstrated that melanoma cells often display higher amounts of MC1R as tumors advance.
Furthermore, the scientists observed significant variations within the primary melanoma cohort itself. Lesions that were ulcerated or measured deeper than 1 mm presented higher MC1R expression than shallower, non-ulcerated tumors. When analyzing clinical outcomes, higher levels of MC1R expression were associated with shorter survival in patients with primary tumors as well as those with metastatic tumors.
Which clinical markers independently predicted survival outcomes?
In addition to examining receptor staining on microscope slides, the investigators performed a multivariable statistical analysis to determine which clinical features predicted patient outcomes. When evaluating the primary melanoma cohort, the multivariable model revealed three independent predictors of worse overall survival:
- Breslow thickness (the measured depth of tumor invasion into the skin)
- Male sex
- Chronic sun exposure
These findings reinforce that traditional clinical characteristics—such as how deeply a lesion has penetrated the skin and past exposure to ultraviolet rays—remain fundamental drivers of long-term prognosis. Readers tracking changes in skin spots should review case reports on moles and melanoma and consult a dermatologist promptly whenever a mole evolves.
What are the design limitations and clinical takeaways of this research?
While the findings provide valuable insight into tumor pathology, readers must interpret this work within its proper context. This was a single retrospective observational study relying on archived tissue microarrays. As the authors highlighted in JCO Precision Oncology, additional studies are necessary to determine the functional biological significance of MC1R in tumor progression and to establish whether measuring receptor levels can reliably predict how patients respond to MC1R-directed drugs in clinical settings.
Importantly, MC1R staining is not currently an everyday clinical screening test for routine mole evaluations, and receptor expression does not replace established prognostic indicators like tumor thickness. Consumers should also remember that unapproved peptides like melanotan I and II sold online are unregulated, carry unknown safety profiles, and are not medical treatments for skin conditions. If you notice a new, changing, or bleeding spot on your skin, schedule an exam with a qualified doctor or dermatologist for an evidence-based clinical evaluation.
Sources
- Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma. (JCO Precision Oncology, 2024)
Published October 31, 2026. Sources are linked in the text. See our Medical Disclaimer.